Tags

Type your tag names separated by a space and hit enter

Statin myopathy: over-rated and under-treated?
Curr Opin Cardiol. 2016 07; 31(4):417-25.CO

Abstract

PURPOSE OF REVIEW

Statins are recommended as first-line therapy for cardiovascular disease. Unfortunately, a proportion of patients cannot tolerate these drugs because of muscle-related side-effects. This review summarizes the definition of statin-related muscle disorders, aetiological factors, and recommended management strategies.

RECENT FINDINGS

A number of consensus groups have defined and classified statin-related muscle disorders, whereas others have suggested diagnostic and management strategies. Mechanisms behind statin-related muscle toxicity have been identified. Therapeutic and clinical investigation pathways have been reviewed and algorithms defined. New drugs have become available to reduce low-density lipoprotein cholesterol levels that are not associated with causing muscle side-effects.

SUMMARY

Statin-related muscle side-effects are common. Secondary causes of muscle disease unmasked by statin therapy should be identified. Most patients can be managed by adjustment of standard treatment protocols.

Authors+Show Affiliations

Department of Metabolic Medicine and Chemical Pathology, Guy's Hospital and St Thomas' Hospital, London, UK.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27258372

Citation

Maghsoodi, Negar, and Anthony S. Wierzbicki. "Statin Myopathy: Over-rated and Under-treated?" Current Opinion in Cardiology, vol. 31, no. 4, 2016, pp. 417-25.
Maghsoodi N, Wierzbicki AS. Statin myopathy: over-rated and under-treated? Curr Opin Cardiol. 2016;31(4):417-25.
Maghsoodi, N., & Wierzbicki, A. S. (2016). Statin myopathy: over-rated and under-treated? Current Opinion in Cardiology, 31(4), 417-25. https://doi.org/10.1097/HCO.0000000000000282
Maghsoodi N, Wierzbicki AS. Statin Myopathy: Over-rated and Under-treated. Curr Opin Cardiol. 2016;31(4):417-25. PubMed PMID: 27258372.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Statin myopathy: over-rated and under-treated? AU - Maghsoodi,Negar, AU - Wierzbicki,Anthony S, PY - 2016/6/4/entrez PY - 2016/6/4/pubmed PY - 2018/5/5/medline SP - 417 EP - 25 JF - Current opinion in cardiology JO - Curr. Opin. Cardiol. VL - 31 IS - 4 N2 - PURPOSE OF REVIEW: Statins are recommended as first-line therapy for cardiovascular disease. Unfortunately, a proportion of patients cannot tolerate these drugs because of muscle-related side-effects. This review summarizes the definition of statin-related muscle disorders, aetiological factors, and recommended management strategies. RECENT FINDINGS: A number of consensus groups have defined and classified statin-related muscle disorders, whereas others have suggested diagnostic and management strategies. Mechanisms behind statin-related muscle toxicity have been identified. Therapeutic and clinical investigation pathways have been reviewed and algorithms defined. New drugs have become available to reduce low-density lipoprotein cholesterol levels that are not associated with causing muscle side-effects. SUMMARY: Statin-related muscle side-effects are common. Secondary causes of muscle disease unmasked by statin therapy should be identified. Most patients can be managed by adjustment of standard treatment protocols. SN - 1531-7080 UR - https://www.unboundmedicine.com/medline/citation/27258372/Statin_myopathy:_over_rated_and_under_treated L2 - http://dx.doi.org/10.1097/HCO.0000000000000282 DB - PRIME DP - Unbound Medicine ER -